Critically ill heart failure patients with increased TyG index face greater risk of acute kidney injury

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-09-05 06:00 GMT   |   Update On 2023-09-05 11:40 GMT

China: An analysis of the MIMIC-IV database has revealed the triglyceride glucose (TyG) index to be a robust and independent predictor of acute kidney injury (AKI) and poor renal outcome in critically ill patients with heart failure (HF). The study findings were published online in Cardiovascular Diabetology on 31 August 2023.

"Our findings indicate that patients with heart failure in a critical condition and increased TyG index face a heightened vulnerability to AKI," the researchers wrote.

The dependable surrogate biomarker TyG index can be used to effectively assess insulin resistance (IR). An elevated TyG index has demonstrated a robust correlation with AKI incidence in various critical care contexts, like contrast-induced AKI. However, there is no clarity on the potential of the TyG index to predict acute kidney injury in critically ill patients with heart failure.

Ningning Ji, Department of Cardiology, Yiwu Central Hospital, Yiwu, Zhejiang, China, and colleagues undertook a retrospective cohort study to examine the prognostic value of the TyG index for AKI in critically ill patients with HF diagnosis.

For this purpose, the researchers non-consecutively selected a cohort of participants from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. They were divided into quartiles based on their TyG index values. The primary outcome was defined as the incidence of AKI.

The secondary endpoint was determined as in-hospital mortality within both the whole study population and the subset of AKI patients. Renal replacement therapy (RRT) use was also included as a secondary endpoint representing renal outcome (the progression of AKI severity).

The association of the TyG index with the AKI risk in HF patients in critical condition was evaluated using a restricted cubic splines model and Cox proportional hazards models. Kaplan-Meier survival analysis was employed to estimate primary and secondary endpoint disparities across groups differentiated by their TyG index.

The study led to the following findings:

  • A total of 1,393 patients were included in the study, with 59% being male. The incidence of AKI was 82.8%.
  • Cox proportional hazards analyses revealed a significant association between the TyG index and the incidence of AKI in critically ill patients with HF.
  • The restricted cubic splines model illustrated the linear relationship between a higher TyG index and increased risk of AKI in this specific patient population.
  • The Kaplan-Meier survival analyses unveiled statistically significant differences in the use of RRT across the subset of AKI patients based on the quartiles of the TyG index.

"Our study expands the applicability of the TyG index to the context of ICU patients with heart failure and establishes that an increased TyG index serves as a predictor and risk stratification tool for acute kidney injury in critically ill patients with HF," the researchers wrote.

"However, further confirmation of causality requires larger prospective studies," they concluded.

Reference:

Yang, Z., Gong, H., Kan, F. et al. Association between the triglyceride glucose (TyG) index and the risk of acute kidney injury in critically ill patients with heart failure: analysis of the MIMIC-IV database. Cardiovasc Diabetol 22, 232 (2023). https://doi.org/10.1186/s12933-023-01971-9


Tags:    
Article Source : Cardiovascular Diabetology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News